Viking Therapeutics Seeks Investor Momentum Ahead of Pivotal Data

Viking Therapeutics enters a pivotal 2026 with Phase 3 data for obesity drug VK2735, oral formulation progress, and key investor presentations driving stock momentum.

Viking Therapeutics is approaching a defining period, with its management team set to engage directly with the investment community during a series of high-profile events. The biotech firm will present at two major investor conferences in Miami as it advances its crucial late-stage obesity treatment program. The central question for shareholders is whether these appearances can inject fresh momentum into the stock, which has recently been trading in a narrow range.

The company’s leadership is scheduled to participate in the Leerink Partners Global Healthcare Conference and the Jefferies Biotech on the Beach Summit between March 8 and 11, 2026. A particular focus will be a fireside chat on March 10, which may offer detailed updates on Viking’s development progress.

Financial Positioning and Pipeline Valuation

Trading at a closing price of $32.46 on the prior Friday, Viking’s shares sit within the middle of their 52-week range of $18.92 to $43.15. The company commands a market capitalization of approximately $3.75 billion. This valuation primarily reflects the potential of its clinical pipeline, as the developer has not yet generated significant revenue.

The VANQUISH Program Takes Center Stage

The core of investor interest is the drug candidate VK2735, a dual agonist targeting GLP-1 and GIP receptors. Following encouraging Phase 2 data that demonstrated weight loss of up to 14.7% over 13 weeks, the pivotal Phase 3 program, named “VANQUISH,” is now underway.

Recruitment for the VANQUISH-1 trial, involving about 4,650 participants, is already complete. Enrollment for the second study, VANQUISH-2, remains ongoing. Results from both trials are anticipated later in 2026 and are considered the most significant near-term catalysts for the company’s stock.

Expanding the Portfolio: Oral Formulation and Novel Approaches

Beyond the injectable version, Viking is accelerating development of a tablet form. The oral formulation of VK2735 is slated to enter Phase 3 testing for obesity in the third quarter of 2026. This strategic move is critical for differentiating Viking in a competitive market dominated by large pharmaceutical companies.

Concurrently, the firm has completed enrollment for a Phase 1 maintenance dose study with roughly 180 participants. This investigation aims to understand how to sustain weight stabilization following a 19-week treatment period, with results also expected in Q3 2026.

Furthermore, Viking is advancing a novel approach beyond GLP-1 therapies. A candidate known as a DACRA (Dual Amylin/Calcitonin Receptor Agonist) is designed for patients who may not respond to conventional treatments. The submission of an Investigational New Drug (IND) application to begin clinical studies is still planned for the current first quarter.

A Defining Year Ahead

The year 2026 is shaping up to be transformative for Viking Therapeutics. A series of concrete milestones are on the horizon, including data readouts from the VANQUISH program, the initiation of the oral Phase 3 study, and pipeline expansion. The upcoming presentations in Miami provide management with a direct opportunity to outline this strategic roadmap to institutional investors.